New ways to weaken MRSA and drug‑resistant pneumonia bacteria
Project 2: Targeting Gram-positive Cell Envelope Assembly
This project is testing methods to break down the protective outer layer of MRSA and drug‑resistant Streptococcus pneumoniae so current antibiotics can work better for people with those infections.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Harvard Medical School NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11121828 on NIH RePORTER |
What this research studies
From a patient's perspective, researchers are hunting for weak spots in the outer coating of two common drug‑resistant bacteria that cause serious infections. One team uses chemistry screens to find small molecules that disturb cell envelope processes and a genetic (transposon) pipeline to quickly link those molecules to the bacterial targets they hit. A second team focuses on understanding and blocking a membrane enzyme called LtaS that helps build the bacterial surface. Together the labs hope to find compounds that restore the power of existing antibiotics like beta‑lactams.
Who could benefit from this research
Good fit: People with confirmed or recurring MRSA infections or drug‑resistant Streptococcus pneumoniae infections (or those at high risk for these infections) would be the most relevant group for future trials or related patient efforts.
Not a fit: Patients with viral infections, infections caused by Gram‑negative bacteria, or those needing immediate treatment are unlikely to see direct benefit from this early, lab‑focused work.
Why it matters
Potential benefit: If successful, this work could lead to new drugs or combination treatments that make common antibiotics effective again against MRSA and drug‑resistant pneumonia.
How similar studies have performed: Targeting the bacterial cell envelope is a proven antibiotic strategy, but the specific focus on LtaS and the pathway‑directed chemical screening approach are newer and remain at an early, preclinical stage.
Where this research is happening
Boston, United States
- Harvard Medical School — Boston, United States (Active)
Researchers
- Principal investigator: Walker, Suzanne — Harvard Medical School
- Study coordinator: Walker, Suzanne
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.